Abbott Laboratories (ABT)
108.33
-0.46
(-0.42%)
USD |
NYSE |
Sep 04, 16:00
108.50
+0.17
(+0.16%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 187.45B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -16.55% |
| Valuation | |
| PE Ratio | 35.02 |
| PE Ratio (Forward) | |
| PS Ratio | 4.062 |
| Price to Book Value | 3.668 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | 0.63 |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.638 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 39.63% |
Profile
| Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment focuses on branded generic pharmaceuticals that are manufactured worldwide and marketed and sold outside the United States, primarily in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternative care testing sites. The Nutritional Products segment oversees the worldwide sale of pediatric and adult nutritional products. The Medical Devices segment offers a broad range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, as well as diabetes care and continuous glucose monitoring products. It also provides neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL. |
| URL | http://www.abbott.com |
| Investor Relations URL | https://www.abbott.com/en-us/investors |
| HQ State/Province | Illinois |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Large Cap Core |
| Next Earnings Release | Oct. 14, 2026 (est.) |
| Last Earnings Release | Jul. 16, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 15, 2026 |
Profile
| Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment focuses on branded generic pharmaceuticals that are manufactured worldwide and marketed and sold outside the United States, primarily in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternative care testing sites. The Nutritional Products segment oversees the worldwide sale of pediatric and adult nutritional products. The Medical Devices segment offers a broad range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, as well as diabetes care and continuous glucose monitoring products. It also provides neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL. |
| URL | http://www.abbott.com |
| Investor Relations URL | https://www.abbott.com/en-us/investors |
| HQ State/Province | Illinois |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Large Cap Core |
| Next Earnings Release | Oct. 14, 2026 (est.) |
| Last Earnings Release | Jul. 16, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 15, 2026 |